Fig. 5 | Signal Transduction and Targeted Therapy

Fig. 5

From: PD-1 antibody camrelizumab plus apatinib and SOX as first-line treatment in patients with AFP-producing gastric or gastro-esophageal junction adenocarcinoma (CAP 06): a multi-center, single-arm, phase 2 trial

Fig. 5The alternative text for this image may have been generated using AI.

Spatial analysis of AFP-G/GEJ adenocarcinoma shows a hierarchy of organization of TICs in diffirent treating efficacy. a Representative multiplex immunofluorescence images of spatial analysis from DCB group and NDB group. Arrowheads in left rows denote CD8+ T and PD-1+CD8+ T cells while those in the right denote FOXP3+CD4+ T cells. b The distribution of the effective score of TICs populations in the tumor parenchyma in 10 µm increments between DCB (n = 14) and NDB (n = 12). Error bars represent mean ± SEM. c Representative multiplex immunofluorescence images of spatial analysis from DCB group and NDB group. Arrowheads denote CD3+ T cells and CD31+ cells. d The effective score of CD3+ T cell populations around CD31+ cells in the tumor parenchyma in 10 µm increments between DCB (n = 14) and NDB (n = 12). P values in b and d were calculated using the two-sided Mann-Whitney U-test. The line in the middle of the box represents the median. The lower and the upper edges of the box are the 1st and 3rd quartiles, respectively. The dots are considered outliers, which are more than 1.5*IQR beyond the lower or upper quartiles

Back to article page